Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.61B |
| 2 |
Microsoft
MSFT
|
+$1.17B |
| 3 |
Broadcom
AVGO
|
+$366M |
| 4 |
Merck
MRK
|
+$343M |
| 5 |
Meta Platforms (Facebook)
META
|
+$260M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$609M |
| 2 |
CMA
Comerica
CMA
|
+$512M |
| 3 |
CADE
Cadence Bank
CADE
|
+$422M |
| 4 |
Johnson & Johnson
JNJ
|
+$331M |
| 5 |
Western Digital
WDC
|
+$277M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.81% |
| 2 | Financials | 17.07% |
| 3 | Industrials | 12.54% |
| 4 | Consumer Discretionary | 10.14% |
| 5 | Healthcare | 9.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2651
Enanta Pharmaceuticals
ENTA
$370M
| $2.57M | ﹤0.01% |
203,252
-8,362
| -4% | -$112K |
|
2652
Axsome Therapeutics
AXSM
$12.3B
| $2.56M | ﹤0.01% |
15,160
+2,729
| +22% | +$471K |
|
2653
Maui Land & Pineapple Co
MLP
$343M
| $2.55M | ﹤0.01% |
165,540
-37,882
| -19% | -$628K |
|
2654
Franklin Financial Services
FRAF
$284M
| $2.52M | ﹤0.01% |
49,391
| – | – |
|
2655
Takeda Pharmaceutical
TAK
$55.7B
| $2.51M | ﹤0.01% |
135,679
-27,607
| -17% | -$485K |
|
2656
TIM SA
TIMB
$9.98B
| $2.5M | ﹤0.01% |
94,380
+2,437
| +3% | +$59.6K |
|
2657
8x8 Inc
EGHT
$262M
| $2.5M | ﹤0.01% |
1,503,539
+164,335
| +12% | +$336K |
|
|
HTT
2658
High Templar Tech Ltd
HTT
$376M
| $2.49M | ﹤0.01% |
1,282,725
-41,137
| -3% | -$116K |
|
2659
Copel
ELPC
$8.57B
| $2.48M | ﹤0.01% |
208,784
+327
| +0.2% | +$3.48K |
|
2660
ProFrac Holding
ACDC
$725M
| $2.42M | ﹤0.01% |
390,420
+238,210
| +157% | +$1.28M |
|
|
MAGN
2661
Magnera Corp
MAGN
$490M
| $2.41M | ﹤0.01% |
253,908
+131,772
| +108% | +$1.68M |
|
2662
Spyre Therapeutics
SYRE
$8.69B
| $2.41M | ﹤0.01% |
47,697
-29,593
| -38% | -$1.12M |
|
2663
Ampco-Pittsburgh
AP
$177M
| $2.39M | ﹤0.01% |
355,427
+20,454
| +6% | +$147K |
|
2664
TechTarget
TTGT
$275M
| $2.38M | ﹤0.01% |
613,238
-80,864
| -12% | -$372K |
|
2665
Crexendo
CXDO
$224M
| $2.35M | ﹤0.01% |
380,327
+52,200
| +16% | +$343K |
|
2666
Magyar Bancorp
MGYR
$119M
| $2.34M | ﹤0.01% |
135,439
| – | – |
|
2667
RF Industries
RFIL
$132M
| $2.34M | ﹤0.01% |
226,965
-14,692
| -6% | -$149K |
|
2668
McCormick & Company Voting
MKC.V
$13.6B
| $2.33M | ﹤0.01% |
46,261
+2,658
| +6% | +$169K |
|
2669
Compass Therapeutics
CMPX
$375M
| $2.32M | ﹤0.01% |
439,784
+98,188
| +29% | +$567K |
|
2670
BV Financial
BVFL
$185M
| $2.31M | ﹤0.01% |
120,933
+5,428
| +5% | +$103K |
|
2671
EVI Industries
EVI
$183M
| $2.3M | ﹤0.01% |
111,750
+4,187
| +4% | +$93.8K |
|
2672
America's Car Mart
CRMT
$27.9M
| $2.26M | ﹤0.01% |
177,191
-40,781
| -19% | -$869K |
|
|
LAC
2673
Lithium Americas
LAC
$1.02B
| $2.23M | ﹤0.01% |
565,135
+393,842
| +230% | +$1.94M |
|
2674
Arcturus Therapeutics
ARCT
$164M
| $2.22M | ﹤0.01% |
288,355
-202,074
| -41% | -$1.47M |
|
2675
Taysha Gene Therapies
TSHA
$1.59B
| $2.18M | ﹤0.01% |
490,472
| – | – |
|
Similar funds
Dimensional Fund Advisors's Q1 2026 Portfolio in Review
As of Q1 2026, Dimensional Fund Advisors held 3,312 positions worth $481B, up 0.98% from $477B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Dimensional Fund Advisors's Q1 2026 filing shows 72 new, 1,935 increased, 1,135 reduced and 97 closed positions. Its largest new stake was Versant Media Group: 1,127,961 shares worth $41.7M. The largest sale was AstraZeneca, an estimated $609M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Financials and Industrials.
- Dimensional Fund Advisors's largest Q1 2026 buy was Versant Media Group: 1,127,961 shares worth $41.7M.
- Dimensional Fund Advisors added most to Amazon in Q1 2026, an estimated $1.61B increase.
- Dimensional Fund Advisors's biggest Q1 2026 reduction was Johnson & Johnson, cutting an estimated $331M.
- Dimensional Fund Advisors fully exited AstraZeneca in Q1 2026, selling an estimated $609M.
- Dimensional Fund Advisors's ten largest holdings make up 17% of its $481B portfolio in Q1 2026.
- Dimensional Fund Advisors opened 72 new positions and closed 97 in Q1 2026.
- Dimensional Fund Advisors's portfolio value rose 0.98% quarter-over-quarter to $481B.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.